Stein C M, Nelson R, Deegan R, He H, Wood M, Wood A J
Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.
J Clin Invest. 1995 Jul;96(1):579-85. doi: 10.1172/JCI118070.
Impaired beta adrenoceptor-mediated vasodilation associated with enhanced sympathetic activity has been reported in established hypertension. We examined whether altered beta adrenoceptor-mediated vasodilation occurs early in the disease process, when structural vascular changes are likely to be less marked, by measurement of forearm blood flow by strain gauge plethysmography after the intraarterial administration of increasing doses of a beta receptor agonist, isoproterenol, in eight subjects with borderline hypertension (BHT) and 13 normotensive (NT) controls. To determine the role of sympathetic activation in the regulation of responsiveness, we measured local sympathetic activity in the forearm by a radioisotope dilution technique. Vasodilation in response to isoproterenol, measured either as changes in forearm blood flow or forearm vascular resistance, was impaired in the BHT group so that flow at the highest dose of isoproterenol (400 ng/min) increased less (15.2 +/- 1.5 ml/100 ml per min) than in the NT group (24.4 +/- 2.4 ml/100 ml per minute) (P < 0.001). Although, systemic norepinephrine spillover was significantly greater in BHT, the difference in blood flow response to isoproterenol was not accounted for by increased local sympathetic activity since forearm norepinephrine spillover at baseline (BHT 1.0 +/- 0.4 ng/min vs. NT 0.64 +/- 0.13 ng/min) and after the administration of isoproterenol 60 ng/min (BHT 5.2 +/- 1.4 ng/min vs. NT 6.0 +/- 1.5 ng/min) and 400 ng/min (BHT 13.5 +/- 2.9 ng/min vs. NT 16.5 +/- 2.7 ng/min) did not differ between the two groups. We therefore conclude that vasodilation in response to isoproterenol is impaired in subjects with BHT and that this impairment is not explained by locally increased basal, or stimulated, sympathetic activity.
在已确诊的高血压患者中,已报道存在与交感神经活动增强相关的β肾上腺素能受体介导的血管舒张功能受损。我们通过对8例临界高血压(BHT)患者和13例血压正常(NT)对照者动脉内注射递增剂量的β受体激动剂异丙肾上腺素后,采用应变片体积描记法测量前臂血流量,来研究在疾病过程早期,当血管结构变化可能不太明显时,β肾上腺素能受体介导的血管舒张是否发生改变。为了确定交感神经激活在反应性调节中的作用,我们采用放射性同位素稀释技术测量前臂局部交感神经活动。以异丙肾上腺素引起的前臂血流量或前臂血管阻力变化来衡量,BHT组对异丙肾上腺素的血管舒张反应受损,以至于在异丙肾上腺素最高剂量(400 ng/min)时血流量增加量(15.2±1.5 ml/100 ml每分钟)低于NT组(24.4±2.4 ml/100 ml每分钟)(P<0.001)。虽然BHT组全身去甲肾上腺素溢出量显著更高,但对异丙肾上腺素的血流反应差异不能用局部交感神经活动增加来解释,因为两组在基线时(BHT 1.0±0.4 ng/min vs. NT 0.64±0.13 ng/min)以及注射60 ng/min(BHT 5.2±1.4 ng/min vs. NT 6.0±1.5 ng/min)和400 ng/min(BHT 13.5±2.9 ng/min vs. NT 16.5±2.7 ng/min)异丙肾上腺素后的前臂去甲肾上腺素溢出量并无差异。因此,我们得出结论,BHT患者对异丙肾上腺素的血管舒张反应受损,且这种损害不能用局部基础或刺激的交感神经活动增加来解释。